TY - JOUR
T1 - Lipid profile components and risk of ischemic stroke
T2 - The Northern Manhattan Study (NOMAS)
AU - Willey, Joshua Z.
AU - Xu, Qiang
AU - Boden-Albala, Bernadette
AU - Paik, Myunghee C.
AU - Moon, Yeseon Park
AU - Sacco, Ralph L.
AU - Elkind, Mitchell S V
PY - 2009/11
Y1 - 2009/11
N2 - Objective: To explore the relationship between lipid profile components and incident ischemic stroke in a strokefree prospective cohort. Design: Population-based prospective cohort study. Setting: Northern Manhattan, New York. Patients: Stroke-free community residents. Intervention: As part of the Northern Manhattan Study, baseline fasting blood samples were collected on strokefree community residents followed up for a mean of 7.5 years. Main Outcome Measures: Cox proportional hazard models were used to calculate hazard ratios and 95% confidence intervals for lipid profile components and ischemic stroke after adjusting for demographic and risk factors. In secondary analyses, we used repeated lipid measures over 5 years from a 10% sample of the population to calculate the change per year of each of the lipid parameters and to impute time-dependent lipid parameters for the full cohort. Results: After excluding those with a history of myocardial infarction, 2940 participants were available for analysis. Baseline high-density lipoprotein cholesterol, triglyceride, and total cholesterol levels were not associated with risk of ischemic stroke. Low-density lipoprotein cholesterol (LDL-C) and non-high-density lipoprotein cholesterol levels were associated with a paradoxical reduction in risk of stroke. There was an interaction with use of cholesterol-lowering medication on follow-up, such that LDL-C level was only associated with a reduction in stroke risk among those taking medications. An LDL-C level greater than 130 mg/dL as a time-dependent covariate showed an increased risk of ischemic stroke (adjusted hazard ratio, 3.81; 95% confidence interval, 1.53-9.51). Conclusions: Baseline lipid panel components were not associated with an increased stroke risk in this cohort. Treatment with cholesterol-lowering medications and changes in LDL-C level over time may have attenuated the risk in this population, and lipid measurements at several points may be a better marker of stroke risk.
AB - Objective: To explore the relationship between lipid profile components and incident ischemic stroke in a strokefree prospective cohort. Design: Population-based prospective cohort study. Setting: Northern Manhattan, New York. Patients: Stroke-free community residents. Intervention: As part of the Northern Manhattan Study, baseline fasting blood samples were collected on strokefree community residents followed up for a mean of 7.5 years. Main Outcome Measures: Cox proportional hazard models were used to calculate hazard ratios and 95% confidence intervals for lipid profile components and ischemic stroke after adjusting for demographic and risk factors. In secondary analyses, we used repeated lipid measures over 5 years from a 10% sample of the population to calculate the change per year of each of the lipid parameters and to impute time-dependent lipid parameters for the full cohort. Results: After excluding those with a history of myocardial infarction, 2940 participants were available for analysis. Baseline high-density lipoprotein cholesterol, triglyceride, and total cholesterol levels were not associated with risk of ischemic stroke. Low-density lipoprotein cholesterol (LDL-C) and non-high-density lipoprotein cholesterol levels were associated with a paradoxical reduction in risk of stroke. There was an interaction with use of cholesterol-lowering medication on follow-up, such that LDL-C level was only associated with a reduction in stroke risk among those taking medications. An LDL-C level greater than 130 mg/dL as a time-dependent covariate showed an increased risk of ischemic stroke (adjusted hazard ratio, 3.81; 95% confidence interval, 1.53-9.51). Conclusions: Baseline lipid panel components were not associated with an increased stroke risk in this cohort. Treatment with cholesterol-lowering medications and changes in LDL-C level over time may have attenuated the risk in this population, and lipid measurements at several points may be a better marker of stroke risk.
UR - http://www.scopus.com/inward/record.url?scp=70449686503&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=70449686503&partnerID=8YFLogxK
U2 - 10.1001/archneurol.2009.210
DO - 10.1001/archneurol.2009.210
M3 - Article
C2 - 19901173
AN - SCOPUS:70449686503
SN - 0003-9942
VL - 66
SP - 1400
EP - 1406
JO - Archives of Neurology
JF - Archives of Neurology
IS - 11
ER -